Bevacizumab抑制人肝癌细胞及其移植瘤的生长

目的探讨Bevacizumab对肝癌细胞株HepG2及荷肝癌裸鼠移植瘤生长的影响。方法不同浓度Bevacizumab处理HepG2细胞48 h后,MTT法检测Bevacizumab对细胞增殖的抑制作用,设不加药物的HepG2细胞为对照组。建立荷肝癌细胞株HepG2裸鼠皮下移植瘤模型,随机分为Bevacizumab组和空白对照组,观察用药前后肿瘤大小,计算抑瘤率;应用免疫组化计算肿瘤微血管密度。结果 Bevacizumab可抑制HepG2细胞增殖;与空白对照组比较,Bevacizumab可延缓移植瘤的生长,MVD值明显降低(P=0.000)。结论 Bevacizumab可直接抑制肝癌细胞株HepG2的增殖;Bevacizumab主要通过抑制新生血管的形成而抑制移植瘤的生长。

Bevacizumab inhibit the growth of hepatocellular carcinoma cells and hepatoma carcinoma xenografts in nude mice

Objective To evaluate the effect of Bevacizumab on the growth of human hepatocellular carcinoma(HCC) HepG2 cells and HCC Xenografts in nude mice.Methods After treatment with different dose of Bevacizumab for 48 h,the proliferation of HepG2 cells was analyzed by MTT assay.The control group was not treated with Bevacizumab.The HepG2 HCC Xenograft models were constructed and divided into two groups: the Bevacizumab group and the control group.Tumor dimensions were recorded and the microvessel density(MVD) was measured by immunohistochemistry.Results Bevacizumab may inhibit the proliferation of HepG2 cells directly.Compared with the control group,the transplanted tumors in the Bevacizumab group grew slower,and MVD in the bevacizumab group decreased significantly(P=0.000).Conclusion Bevacizumab could inhibit the proliferation of HepG2 cells and the growth of HCC xenograft mainly through reducing angiogenesis.